Engineers Gate Manager’s Apellis Pharmaceuticals APLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-19,197
| Closed | -$772K | – | 2221 |
|
|
2026
Q1 | $772K | Buy |
+19,197
| New | +$414K | 0.01% | 1176 |
|
|
2025
Q4 | – | Sell |
-66,336
| Closed | -$1.5M | – | 2087 |
|
|
2025
Q3 | $1.5M | Buy |
66,336
+7,618
| +13% | +$178K | 0.02% | 940 |
|
|
2025
Q2 | $1.02M | Buy |
58,718
+16,546
| +39% | +$306K | 0.01% | 1108 |
|
|
2025
Q1 | $922K | Buy |
+42,172
| New | +$1.17M | 0.02% | 1109 |
|
|
2024
Q4 | – | Sell |
-67,625
| Closed | -$1.95M | – | 2208 |
|
|
2024
Q3 | $1.95M | Buy |
67,625
+55,456
| +456% | +$2.05M | 0.04% | 664 |
|
|
2024
Q2 | $467K | Buy |
12,169
+6,120
| +101% | +$277K | 0.01% | 1256 |
|
|
2024
Q1 | $356K | Buy |
6,049
+2,221
| +58% | +$142K | 0.01% | 1377 |
|
|
2023
Q4 | $229K | Sell |
3,828
-22,533
| -85% | -$1.14M | 0.01% | 1580 |
|
|
2023
Q3 | $1M | Buy |
26,361
+22,846
| +650% | +$1M | 0.04% | 706 |
|
|
2023
Q2 | $320K | Buy |
+3,515
| New | +$303K | 0.01% | 1279 |
|
|
2022
Q2 | – | Sell |
-10,678
| Closed | -$543K | – | 1884 |
|
|
2022
Q1 | $543K | Buy |
+10,678
| New | +$471K | 0.02% | 1026 |
|
|
2021
Q2 | – | Sell |
-7,530
| Closed | -$323K | – | 1583 |
|
|
2021
Q1 | $323K | Sell |
7,530
-1,760
| -19% | -$83.3K | 0.02% | 1271 |
|
|
2020
Q4 | $531K | Buy |
+9,290
| New | +$393K | 0.02% | 943 |
|
Other funds holding APLS
Engineers Gate Manager's APLS Position: Q2 2026 in Review
Engineers Gate Manager sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 19,197 shares — an estimated $772K sold.
Engineers Gate Manager first reported a position in APLS in Q4 2020 and held it in 13 quarters. The position peaked at $1.95M in Q3 2024. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.
- Engineers Gate Manager reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Engineers Gate Manager sold 19,197 Apellis Pharmaceuticals shares in Q2 2026, an estimated $772K.
- Engineers Gate Manager first reported a position in Apellis Pharmaceuticals in Q4 2020 and held it in 13 quarters.
- Engineers Gate Manager's Apellis Pharmaceuticals position peaked at $1.95M in Q3 2024.
- 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.
Based on Engineers Gate Manager's 13F filing for Q2 2026, filed 14 Aug 2026.